- 1. (Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase
- [A modified form of asparaginase, an anticancer drug that belongs to the family of drugs derived from enzymes. ( NCI )] (UMLS (NCI) C0071568) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Enzyme =[AN000] ANTINEOPLASTICS;
ASPARAGINASE;
Glycol, polyethylene;
(Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase =(Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase;
PEGASPARGASE 750 UNT/ML;
| - 51. model
- [representation of a process, system, or subject area that can be manipulated to demonstrate the effects that various actions will have on the process, system, or subject area; generally developed for understanding, analysis, improvement, and/or replacement of the process, system, or subject area. ( CSP )] (UMLS (CSP) C0026336) =Research Device; Intellectual Product =health science research;
=alternatives to animals in research;
biological model;
chemical model;
genetic model;
psychological model;
enzyme model;
health care model;
membrane model;
phantom model;
social model;
physical model;
disease/disorder model;
Math Models |
- 2. 1 month (30 days) post challenge
- (UMLS (HL7) C1547066) =Temporal Concept =Time delay post challenge;
| - 52. Model date
- [A text version of the last modified date formatted like "19970606" ( HL7V3.0 )] (UMLS (HL7) C1554148) =Idea or Concept =HL7DefinedRoseProperty;
|
- 3. 2 months (60 days) post challenge
- (UMLS (HL7) C1547073) =Temporal Concept =Time delay post challenge;
| - 53. Model description
- [Contains the textual description of the model. ( HL7V3.0 )] (UMLS (HL7) C1554149) =Idea or Concept =HL7DefinedRoseProperty;
|
- 4. 3 months (90 days) post challenge
- (UMLS (HL7) C1547077) =Temporal Concept =Time delay post challenge;
| - 54. model design
- [ ] (UMLS (CSP) C0920594) =Intellectual Product
|
- 5. 8-MOP
- (UMLS (NCI) C0740123) =Organic Chemical; Pharmacologic Substance ;
| - 55. model design/development
- [index with a specific model term. ( CSP )] (UMLS (CSP) C0596955) =Intellectual Product ;
=technology/technique development;
|
- 6. lower urinary tract
- [Subdivision of urinary system which consists of the urinary bladder and the urethra. ( UWDA )] (UMLS (CSP) C0729866) =Body System
| - 56. model development
- [ ] (UMLS (CSP) C0920595) =Intellectual Product
|
- 7. Mo
- [hard, silvery-white metallic element, symbol Mo, atomic number, 42; an essential trace element as a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase. ( CSP )] (UMLS (NCI) C0026402) =Biologically Active Substance; Element, Ion, or Isotope =Micronutrient;
heavy metal;
[TN499] ELECTROLYTES/MINERALS, OTHER;
=ammonium molybdate;
Disodium Molybdate;
99 Molybdenum;
MOLYBDENUM (AS SODIUM);
ammonium molybdate;
CERTAGEN TAB;
CHOICE DM LIQUID,BOTTLE,1000ML;
ISOCAL LIQUID,CAN,240ML;
ISOCAL LIQUID,CAN,360ML;
ISOCAL LIQUID,CAN,960ML;
MATERNA PRENATAL TAB;
MOLYBDENUM 0.114 MCG/ML;
MOLYBDENUM 15 MCG;
MOLYBDENUM 160 MCG;
MOLYBDENUM 19 MCG/240ML;
MOLYBDENUM 24 MCG/240ML;
MOLYBDENUM 25 MCG;
MOLYBDENUM 25 MCG/240ML;
MOLYBDENUM 26 MCG/240ML;
MOLYBDENUM 27 MCG/240ML;
MOLYBDENUM 29 MCG/240ML;
MOLYBDENUM 38 MCG/240ML;
MOLYBDENUM 8.5 MCG/240ML | - 57. Model identifier
- [Holds the unique identifier assigned to this model. ( HL7V3.0 )] (UMLS (HL7) C1554150) =Idea or Concept =HL7DefinedRoseProperty;
|
- 8. mo
- [One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks. (NCI) ( NCI )] (UMLS (NCI) C0439231) =Temporal Concept =UnitOfMeasureAtomInsens;
UnitOfMeasureAtomSens | - 58. Model name
- [Holds the formal name for the model ( HL7V3.0 )] (UMLS (HL7) C1554151) =Idea or Concept =HL7DefinedRoseProperty;
|
- 9. MoAb 3H1 anti-idiotype vaccine
- [A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA. (NCI04) ( NCI )] (UMLS (NCI) C0393051) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 59. Model version
- [A text version of the version number like "V 30-08" ( HL7V3.0 )] (UMLS (HL7) C1554152) =Idea or Concept =HL7DefinedRoseProperty;
|
- 10. MOAB BrE-3, Yttrium Y 90
- [A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. (NCI04) ( NCI )] (UMLS (NCI) C0935731) Yttrium Y 90 Monoclonal Antibody BrE-3 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 60. Modeling
- [The use of statistical analysis, computer analysis, or model organisms to predict outcomes of research. (doegenomes.org) ( NCI )] (UMLS (NCI) C0870071) =Research Activity; Intellectual Product
|
- 11. MOAB CC49-deltaCH2
- [A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72). TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04) ( NCI )] (UMLS (NCI) C1134500) MOAB HCC49DCH2;
MoAb HuCC49DeltaCH2;
Monoclonal Antibody CC49-delta CH2;
Monoclonal Antibody HCC49DCH2 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 61. Modeling and Methodology
- [Modeling and Methodology ( HL7V3.0 )] (UMLS (HL7) C1554090) =Intellectual Product =HL7CommitteeIDInRIM;
|
- 12. MoAb CD20
- (UMLS (NCI) C0796614) monoclonal antibody, CD20 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 62. ModelMediaType
- [Model media type. ( HL7V3.0 )] (UMLS (HL7) C1699888) =Classification ;
=MediaType;
=VRML Model;
|
- 13. MoAb D6.12
- [A murine IgG2a monoclonal antibody directed against a 48 kDa antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium. MoAb D6.12 has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This MoAb, either alone or in combination with other immunotherapeutic agents, may have possible diagnostic or therapeutic applications in gastrointestinal cancers. ( NCI )] (UMLS (NCI) C1134661) MoAb D612;
Monoclonal Antibody D6.12;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 63. Modem
- [A telephone number served by a modem device [http://www.ietf.org/rfc/rfc3966.txt and http://www.ietf.org/rfc/rfc2806.txt]. ( HL7V3.0 )] (UMLS (HL7) C1555020) =Idea or Concept =URLScheme;
|
- 14. MOAB HER2/TAX
- (UMLS (NCI) C0338364) =Therapeutic or Preventive Procedure
| - 64. Moderate
- (UMLS (HL7) C0694627) =Qualitative Concept =Allergy Severity;
◊ [Indicates the condition may result in noticable adverse adverse consequences but is unlikely to be life-threatening or cause permanent injury. ( HL7V3.0 )] (UMLS (HL7) C0205081) Qualitative Concept ; SeverityObservation; ◊ (UMLS (HL7) C1547226) Intellectual Product Severity of Illness Code; |
- 15. MOAB HMFG1, yttrium Y 90
- [A radioimmunoconjugate of humanized monoclonal antibody (MoAb) HMFG1 labelled with Yttrium 90 (Y-90). MoAb MFG1 was raised against Human Milk Fat Globules and reacts with an epitope (PDTR) in the protein core of MUC1 mucins, which are up-regulated in human breast and other carcinomas.Y-90 MoAb HMFG1 delivers beta particle emitting Y-90 radionuclide directly to tumor cells that express MUC1, thereby may be used in radioimmunotherapy of cancers. ( NCI )] (UMLS (NCI) C0879349) monoclonal antibody HMFG1, yttrium Y 90;
Y 90 MoAb HMFG1;
Y 90 Monoclonal Antibody HMFG1;
yttrium Y 90 MOAB HMFG1;
Yttrium Y 90 Monoclonal Antibody HMFG1 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 65. Moderate Colon Dysplasia
- (UMLS (NCI) C0586368) =Disease or Syndrome
|
- 16. MoAb Hu1D10
- (UMLS (NCI) C0879351) MoAb: Hu1D10;
Monoclonal antibody 1D10;
Monoclonal Antibody Hu1D10 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 66. Moderate Columnar Cell Atypia
- (UMLS (NCI) C0333878) =Cell or Molecular Dysfunction
|
- 17. MOAB LL2, yttrium Y 90
- [A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 humanized epratuzumab binds to tumor cells expressing CD222, delivering a cytotoxic dose of beta radiation. (NCI04) ( NCI )] (UMLS (NCI) C0879352) Monoclonal antibody LL2, yttrium Y 90;
Y 90 Humanized Monoclonal Antibody LL2;
Y 90 MoAb LL2;
Y 90 monoclonal antibody LL2;
Y90 Humanized Epratuzumab;
Yttrium 90 Humanized Epratuzumab;
Yttrium Y 90 Humanized Epratuzumab;
Yttrium Y 90 Humanized Monoclonal Antibody LL2;
yttrium Y 90 MOAB LL2 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 67. Moderate Cytologic Atypia
- (UMLS (NCI) C0333867) =Cell or Molecular Dysfunction
|
- 18. MOAB Lym-1, yttrium Y 90
- [A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. Y-90 MoAb Lym-1 delivers Y-90 radionuclide directly to tumor cells that express HLA-DR antigen, thereby may be used in radioimmunotherapy of cancers. ( NCI )] (UMLS (NCI) C0796675) monoclonal antibody Lym-1, yttrium Y 90;
Y 90 MoAb Lym-1;
Y 90 Monoclonal Antibody Lym-1;
yttrium Y 90 MOAB Lym-1;
Yttrium Y 90 Monoclonal Antibody Lym-1 =Pharmacologic Substance; Immunologic Factor ;
| - 68. Moderate Dysplasia
- (UMLS (NCI) C0334047) =Cell or Molecular Dysfunction
|
- 19. MOAB m170, yttrium Y 90
- [A radioimmunoconjugate of m170 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb m170 is a murine MoAb that recognizes MUC-1 antigen present on the surface of many adenocarcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses. ( NCI )] (UMLS (NCI) C0796669) monoclonal antibody m170, yttrium Y 90;
Y 90 MoAb m170;
Y 90 Monoclonal Antibody m170;
yttrium Y 90 MOAB m170;
Yttrium Y 90 Monoclonal Antibody m170 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 69. Moderate Dysplasia of Rectum
- (UMLS (NCI) C0586372) =Disease or Syndrome
|
- 20. MOAB M195, yttrium Y 90
- [A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses. ( NCI )] (UMLS (NCI) C0879572) monoclonal antibody M195, yttrium Y 90;
Y 90 MoAb M195;
Y 90 Monoclonal Antibody M195;
Yttrium Y 90 Monoclonal Antibody M195 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 70. Moderate Esophageal Dysplasia
- (UMLS (NCI) C0586356) =Disease or Syndrome
|
- 21. MOAB MN-14, yttrium Y 90
- [A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04) ( NCI )] (UMLS (NCI) C0879253) monoclonal antibody MN-14, yttrium Y 90;
Y 90 MoAb MN-14;
Y 90 Monoclonal Antibody MN-14;
Yttrium 90 Monoclonal Antibody MN-14;
yttrium Y 90 MOAB MN-14;
Yttrium Y 90 Monoclonal Antibody MN-14 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 71. Moderate Glandular Cell Atypia
- (UMLS (NCI) C0333882) =Cell or Molecular Dysfunction
|
- 22. MoAb muJ591
- [A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. ( NCI )] (UMLS (NCI) C0678086) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 72. Moderate Koilocytotic Atypia
- (UMLS (NCI) C0333898) =Cell or Molecular Dysfunction
|
- 23. MoAb MX35 F(ab')2
- [The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against tumor cell that express this glycoprotein. Containing only the antigen-binding fragment of the Ig molecule, MoAb MX35 F(ab')2 offers the advantages of smaller size and lower cross-reactivity compared to complete antibodies. ( NCI )] (UMLS (NCI) C0393012) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 73. Moderate or severe vision impairment, better eye; profound vision impairment of lesser eye
- [ ] (UMLS (ICD9CM) C0339701) =Disease or Syndrome
|
- 24. MoAb R24
- [An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells. Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. (NCI04) ( NCI )] (UMLS (NCI) C0279226) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 74. Moderate or severe vision impairment, both eyes
- [ ] (UMLS (ICD9CM) C0155040) =Disease or Syndrome
|
- 25. Moapa Band of Paiute Indians of the Moapa River In
- (UMLS (HL7) C1554380) =Population Group =NativeEntityContiguous;
| - 75. Moderate or severe vision impairment, one eye
- [ ] (UMLS (ICD9CM) C0155058) =Disease or Syndrome
|
- 26. Moban
- (UMLS (NCI) C0733813) =Organic Chemical; Pharmacologic Substance ;
| - 76. Moderate Squamous Cell Atypia
- (UMLS (NCI) C0333871) =Cell or Molecular Dysfunction
|
- 27. Mobec
- (UMLS (NCI) C0592680) =Organic Chemical; Pharmacologic Substance
| - 77. Moderate Transitional Cell Atypia
- (UMLS (NCI) C0333886) =Cell or Molecular Dysfunction
|
- 28. Mobile
- (UMLS (HL7) C1552449) =Manufactured Object; Health Care Related Organization =Clinic/Center;
| - 78. Moderately Differentiated Lesion
- (UMLS (NCI) C1334790) =Finding
|
- 29. Mobile
- [Moving or capable of moving readily. ( NCI )] (UMLS (NCI) C0231435) =Functional Concept
| - 79. Moderately Differentiated Malignant Neoplasm
- (UMLS (NCI) C1334791) =Neoplastic Process
|
- 30. mobile contact
- [A telecommunication device that moves and stays with its owner. May have characteristics of all other use codes, suitable for urgent matters, not the first choice for routine business. ( HL7V3.0 )] (UMLS (HL7) C1550705) =Idea or Concept =TelecommunicationAddressUse;
| - 80. Moderately Differentiated Prostate Adenocarcinoma
- (UMLS (NCI) C1334792) =Neoplastic Process
|
- 31. mobile health unit
- [movable facilities in which diagnostic and therapeutic services are provided to the community. ( CSP )] (UMLS (CSP) C0026331) =Health Care Related Organization ;
=Health Care Facility;
| - 81. Moderately probable
- (UMLS (HL7) C1546987) =Idea or Concept =Relatedness Assessment;
|
- 32. Mobile Mammography
- (UMLS (HL7) C1552450) =Intellectual Product ;
=Clinic/Center;
| - 82. moderately susceptible
- [Moderately susceptible ( HL7V3.0 )] (UMLS (HL7) C0442815) =Finding =ObservationInterpretationSusceptibility;
|
- 33. Mobile Phone
- [Mobile communications system that uses a combination of radio wave transmission and conventional telephone switching to permit telephone communication to and from mobile users within a specified area. ( NCI )] (UMLS (NCI) C1136360) Mobile Telephone =Manufactured Object
| - 83. Moderately susceptible. Indicates for microbiology susceptibilities only.
- (UMLS (HL7) C1548138) =Qualitative Concept =Abnormal flags;
|
- 34. mobile spasm
- [ ] (UMLS (CSP) C0597925) =Sign or Symptom ;
| - 84. Moderil
- (UMLS (NCI) C0950889) =Organic Chemical; Pharmacologic Substance
|
- 35. Mobile Unit
- (UMLS (HL7) C1548342) =Intellectual Product =Visit User Code;
| - 85. modification
- [Respond with exceptions, completions and modifications or revisions done before completion ( HL7V3.0 )] (UMLS (HL7) C1554963) =Qualitative Concept =ResponseLevel;
|
- 36. Mobile Unit
- [Location (mobile) where healthcare service was delivered. ( HL7V3.0 )] (UMLS (HL7) C1555593) =Manufactured Object =DedicatedNonClinicalLocationRoleType;
=Ambulance;
| - 86. modification for handicapped
- [ ] (UMLS (CSP) C0598558) =Therapeutic or Preventive Procedure
|
- 37. Mobility impaired
- (UMLS (HL7) C1550447) =Idea or Concept =PersonDisabilityType;
=Requires crutches;
Requires walker;
Requires wheelchair;
Requires gurney;
Requires crib;
| - 87. Modified assignment
- (UMLS (HL7) C1549441) =Idea or Concept =Assignment of Benefits;
|
- 38. Mobilization of other joints
- [ ] (UMLS (ICD9CM) C0178014) =Therapeutic or Preventive Procedure
| - 88. Modified By
- [Indicates the person or authoritative body who changed an item. ( NCI )] (UMLS (NCI) C0205349) =Functional Concept
|
- 39. MOBILIZATION OF SPINE
- [ ] (UMLS (ICD9CM) C0178013) =Therapeutic or Preventive Procedure
| - 89. Modified from original specimen
- (UMLS (HL7) C1548800) =Idea or Concept =Specimen Child Role;
|
- 40. Mobist
- (UMLS (NCI) C0935953) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 90. Modified Masson trichrome stain
- [Stain, Modified Masson trichrome ( HL7V3.0 )] (UMLS (HL7) C1294298) =Laboratory Procedure =ObservationMethod;
|
- 41. Moctamide
- (UMLS (NCI) C0066674) =Lipid; Pharmacologic Substance
| - 91. Modified Mastectomy
- [(mas-TEK-toe-mee) Surgery for breast cancer in which the breast, some of the lymph nodes under the arm, the lining over the chest muscles, and sometimes part of the chest wall muscles are removed. ( NCI )] (UMLS (NCI) C0024883) =Therapeutic or Preventive Procedure
|
- 42. Mod 10 algorithm
- (UMLS (HL7) C1546487) =Intellectual Product =Check digit scheme;
| - 92. Modified Radical Neck Dissection
- (UMLS (NCI) C0193864) =Therapeutic or Preventive Procedure
|
- 43. Mod 11 algorithm
- (UMLS (HL7) C1546488) =Intellectual Product =Check digit scheme;
| - 93. MODIFIED SMALLPOX
- (UMLS (ICD9CM) C0037358) =Disease or Syndrome
|
- 44. MOD MENTAL RETARDATION
- (UMLS (ICD9CM) C0026351) =Mental or Behavioral Dysfunction ;
| - 94. Modified Subscription
- [Modified subscription to a query server. ( HL7V3.0 )] (UMLS (HL7) C1550179) =Idea or Concept =Modify indicator;
ModifyIndicator |
- 45. MOD NONPROLF DB RETINOPH
- [ ] (UMLS (ICD9CM) C0730277) Moderate nonproliferative diabetic retinopathy =Disease or Syndrome
| - 95. Modified trichrome stain
- [Stain, Modified trichrome ( HL7V3.0 )] (UMLS (HL7) C1294299) =Laboratory Procedure =ObservationMethod;
|
- 46. Mod. Martin-Lewis Agar
- (UMLS (HL7) C1548735) =Laboratory Procedure =Specimen Collection Method;
| - 96. Modifier approved for ASC/HOPD use, inappropriate for code
- (UMLS (HL7) C1547510) =Intellectual Product =Modifier Edit Code;
|
- 47. MODAFINIL
- [A drug that is being studied as a treatment for fatigue in patients with cancer. It belongs to the family of drugs called stimulants. ( NCI )] (UMLS (NCI) C0066677) =Organic Chemical; Pharmacologic Substance =Benzhydryl Compounds;
[CN809] CNS STIMULANTS, OTHER =MODAFINIL 100 MG;
MODAFINIL 200 MG;
| - 97. Modifier does NOT exist
- (UMLS (HL7) C1547506) =Intellectual Product =Modifier Edit Code;
|
- 48. Modality
- (UMLS (HL7) C1547664) =Diagnostic Procedure =HL7 Vocabulary Version 2.5;
=colposcopy;
cystoscopy;
Diagnostic ultrasound of heart;
Endoscopic;
Fluorescein angiography;
Magnetic resonance spectroscopy;
Fundoscopy;
Laparoscopic;
FDG-PET;
Thermography;
CAT;
Diagnosis (US);
Magnetic resonance angiography;
Color flow Doppler;
Angioscopy;
Biomagnetic imaging;
Computed radiography;
Duplex Doppler;
Diapanography;
Digital microscopy;
Laser surface scan;
Nuclear Medicine (radioisotope study);
Other;
Radio fluoroscopy;
Single photon emission computed tomography (SPECT);
X-ray Angiography | - 98. Modifier Edit Code
- (UMLS (HL7) C1547845) =Intellectual Product =HL7 Vocabulary Version 2.5;
=Modifier does NOT exist;
Modifier present, no errors;
Modifier invalid;
Modifier NOT approved for ASC/HOPD use;
Modifier approved for ASC/HOPD use, inappropriate for code;
Modifier edit code unknown |
- 49. Modality
- [A specific manner, characteristic, pattern of application or the employment of, any therapeutic agent or method of treatment, especially involving the physical treatment of a condition. ( NCI )] (UMLS (NCI) C0695347) =Idea or Concept
| - 99. Modifier edit code unknown
- (UMLS (HL7) C1547511) =Intellectual Product =Modifier Edit Code;
|
- 50. Mode of Arrival Code
- (UMLS (HL7) C1547811) =Machine Activity =HL7 Vocabulary Version 2.5;
=Ambulance;
Car;
Helicopter;
Public Transport;
Unknown;
On foot;
Other;
| - 100. Modifier invalid
- (UMLS (HL7) C1547508) =Intellectual Product =Modifier Edit Code;
|
home
